Pharmanutra S.p.A.
PHN
Rank in Stocks
#9676
Pharmanutra S.p.A. functions as a pharmaceutical and nutraceutical enterprise,... Pharmanutra S.p.A. functions as a pharmaceutical and nutraceutical enterprise, focusing on the research, development, design, and marketing of nutritional supplements and medical devices. Its market reach extends across Italy, other parts of Europe, the Middle East, the Far East, and globally. Moreover, the company manufactures and promotes pharmaceuticals, medical devices, over-the-counter (OTC) items, and nutraceuticals specifically for the pediatric population. Furthermore, Pharmanutra is a producer and supplier of raw materials and active ingredients to the food, pharmaceutical, and dietary supplement industries. Its diverse product portfolio features prominent brands like the SiderAL series (including SiderAL Forte, SiderAL Folic, Cardio SiderAL, SiderAL Med), the Cetilar range (Cetilar Crema, Cetilar Patch, Tape), along with ApportAL, UltraMag, Gestalys DHA, Novomega, Bonecal, and DiKappa 2. These products are distributed and sold through a network comprising sales representatives, wholesalers, pharmacies, and para-pharmacies. Established in 2003, the company's base of operations is in Pisa, Italy.
Share Price
$84.51
Last synced: 2026-11-09
Market Cap
$809.17M
Change (1 day)
1.89%
Change (1 year)
44.37%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Pharmanutra S.p.A. (PHN)
Category
Healthcare
Operating Margin for Pharmanutra S.p.A. (PHN)
Operating Margin as of November 2026 TTM: -2.92%
According to Pharmanutra S.p.A.'s latest financial reports, its current operating margin (TTM) is -2.92%. At the end of 2025 the company had an operating margin of 23.02%.
Operating Margin history for Pharmanutra S.p.A. from 2015 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | -2.92% | -112.68% |
| 2025 | 23.02% | -2.33% |
| 2024 | 23.57% | 1.95% |
| 2023 | 23.12% | -16.32% |
| 2022 | 27.63% | 0.73% |
| 2021 | 27.43% | 21.37% |
| 2020 | 22.60% | -0.92% |
| 2019 | 22.81% | -10.65% |
| 2018 | 25.53% | 8.92% |
| 2017 | 23.44% | 25.15% |
| 2016 | 18.73% | 15.12% |
| 2015 | 16.27% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 19.41% | -106.65% |
DE
|
|
| 19.68% | -106.74% |
DE
|
|
| 13.26% | -104.54% |
JP
|
|
| 17.08% | -105.85% |
CH
|
|
| 14.92% | -105.11% |
IL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Pharmanutra S.p.A.'s operating margin
What is Pharmanutra S.p.A.'s operating margin?
Pharmanutra S.p.A.'s operating margin is -2.92%, as of Nov 2026.
What was Pharmanutra S.p.A.'s operating margin in 2025?
In 2025, Pharmanutra S.p.A.'s operating margin was 23.02%, compared with 23.57% in 2024.
How has Pharmanutra S.p.A.'s operating margin changed since 2020?
From 2020 to 2025, Pharmanutra S.p.A.'s operating margin was highest in 2022 (27.63%) and lowest in 2020 (22.60%).
How does Pharmanutra S.p.A.'s operating margin compare with similar companies?
Pharmanutra S.p.A.'s operating margin (-2.92%) is lower than that of all 5 similar companies listed above. The highest among them is Merck KGaA, with 19.68%.